"Half-Life" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity.
| Descriptor ID |
D006207
|
| MeSH Number(s) |
G01.910.405
|
| Concept/Terms |
Half-Life- Half-Life
- Half Life
- Half-Lifes
- Halflife
- Halflifes
|
Below are MeSH descriptors whose meaning is more general than "Half-Life".
Below are MeSH descriptors whose meaning is more specific than "Half-Life".
This graph shows the total number of publications written about "Half-Life" by people in this website by year, and whether "Half-Life" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 3 | 3 |
| 1995 | 0 | 6 | 6 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 5 | 5 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 5 | 5 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 5 | 5 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 7 | 7 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 4 | 4 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 11 | 11 |
| 2011 | 0 | 6 | 6 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 5 | 5 |
| 2015 | 0 | 5 | 5 |
| 2016 | 0 | 6 | 6 |
| 2017 | 0 | 6 | 6 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 5 | 5 |
| 2021 | 0 | 4 | 4 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Half-Life" by people in Profiles.
-
In vitro model to simulate multiple drugs with distinct elimination half-lives. Int J Antimicrob Agents. 2023 Oct; 62(4):106924.
-
Deep mutational scanning and massively parallel kinetics of plasminogen activator inhibitor-1 functional stability to probe its latency transition. J Biol Chem. 2022 12; 298(12):102608.
-
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med. 2022 03 09; 14(635):eabl8124.
-
The half-life of maternal transplacental antibodies against diphtheria, tetanus, and pertussis in infants: an individual participant data meta-analysis. Vaccine. 2022 01 24; 40(3):450-458.
-
Formulation, Optimization, In Vitro and In Vivo Evaluation of Saxagliptin-Loaded Lipospheres for an Improved Pharmacokinetic Behavior. Biomed Res Int. 2021; 2021:3849093.
-
Longitudinal Impact of Acute Spinal Cord Injury on Clinical Pharmacokinetics of Riluzole, a Potential Neuroprotective Agent. J Clin Pharmacol. 2021 09; 61(9):1232-1242.
-
Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1. Cancer Chemother Pharmacol. 2021 08; 88(2):359-365.
-
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes. J Med Chem. 2021 05 13; 64(9):5384-5403.
-
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem. 2020 11 12; 63(21):12957-12977.
-
The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nat Cell Biol. 2020 11; 22(11):1332-1345.